ProCE Banner Activity


Keeping Up in NSCLC: Actionable Biomarkers and Their Impact on Treatment

PCE On Demand Live Presentation

Over the past several years, numerous targeted therapies have been approved for advanced non-small cell lung cancer (NSCLC), providing more options for eligible patients and further highlighting the importance of biomarker testing. Additionally, with recent approvals in the adjuvant setting, there is now a role for certain biomarker testing in early-stage NSCLC. As the therapeutic landscape for NSCLC continues to rapidly evolve, healthcare professionals must remain up to date on testing recommendations and treatment options for patients with NSCLC, including those with actionable biomarkers. In this video lecture, an expert discusses the importance of comprehensive biomarker testing in NSCLC, methods of testing, who and when to test, and available targeted therapies for those with identified actionable biomarkers.

Physician Assistants: maximum of 1.00 hours of AAPA Category 1 CME credits Registered Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacology credit

Released: August 15, 2022

Expiration: August 14, 2023

No longer available for credit.



Beth Sandy

Beth Sandy, MSN, CRNP

Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania


This program was cosupported by educational grants from: AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo, Inc; Genentech, a member of the Roche Group; GlaxoSmithKline; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Lilly; Merck Sharp & Dohme Corp.; Regeneron Pharmaceuticals, Inc and Sanofi; and Seagen Inc. and Astellas.

This activity is supported by an educational grant from: Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Provided by

ProCE Banner


Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Target Audience

Oncology NPs, PAs, and nurses

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify actionable biomarkers in NSCLC

  • Describe guideline-recommended testing strategies for NSCLC

  • Develop treatment strategies based on actionable biomarkers in patients with NSCLC


All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Rasheda Persinger, MSN, AGNP-C, AOCNP: consultant/advisor/speaker: AstraZeneca, Guardiant Health, Pfizer.

Beth Sandy, MSN, CRNP: consultant/advisor/speaker: Amgen, AstraZeneca, Janssen, Jazz, Merck, Takeda.

None of the members of the Planning Committee or PCE staff have any relevant financial relationships to disclose, except Beth Sandy, MSN, CRNP, and Rasheda Persinger, MSN, AGNP-C, AOCNP as noted above.

Instructions for Credit

Participants wishing to earn CE/CME credit must:

  1. View the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete evaluation form

The estimated time to complete this activity is 1.00 hour.

Release date: August 15, 2022
Expiration date: August 14, 2023


On-demand webcast


The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.



Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit

NP course advisors: Beth Sandy, MSN, CRNP, Abramson Cancer Center, Philadelphia, Pennsylvania; Rasheda Persinger, MSN, AGNP-C, AOCNP, Johns Hopkins University, Washington, DC

AAPA Credit Designation

Joint AccreditationPracticing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until August 14, 2023. PAs should only claim credit commensurate with the extent of their participation.

PA course advisor: Jessica Garner, DMSc, PA-C, University of the Pacific, Sacramento, California

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credits for learning and change.

Additional Information

Program Medium

This program has been made available online.